Cargando…
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials
BACKGROUND: Patient-reported outcome measures (PROMs) are often used in clinical research, but little is known about their performance as longitudinal outcomes. METHODS: We used data from ASCEND, a large SPMS trial (n = 889), to investigate changes on the Short Form Health Survey 36 (SF-36 v2) and t...
Autores principales: | Strijbis, Eva MM, Repovic, Pavle, Mostert, Jop, Bowen, James D, Uitdehaag, Bernard MJ, Cutter, Gary, Koch, Marcus W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315187/ https://www.ncbi.nlm.nih.gov/pubmed/35876467 http://dx.doi.org/10.1177/13524585221105465 |
Ejemplares similares
-
Impact of clinical outcomes and imaging measures on health-related
quality of life in secondary progressive MS
por: W Koch, Marcus, et al.
Publicado: (2021) -
MRI brain volume loss, lesion burden, and clinical outcome in
secondary progressive multiple sclerosis
por: Koch, Marcus W, et al.
Publicado: (2021) -
Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023) -
A comparison of clinical outcomes in PPMS in the INFORMS original trial data set
por: Koch, Marcus W, et al.
Publicado: (2021) -
Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)